Cargando…

A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors

Gastric cancer is a leading cause of cancer-related deaths with considerable heterogeneity among patients. Appropriate classifications are essential for prognosis prediction and individualized treatment. Although immunotherapy showed potential efficacy in a portion of patients with gastric cancer, f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Song, Gao, Jing, Xu, Qian, Zhang, Xue, Huang, Miao, Dai, Xin, Huang, Kai, Liu, Lian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232232/ https://www.ncbi.nlm.nih.gov/pubmed/34177954 http://dx.doi.org/10.3389/fimmu.2021.693314

Ejemplares similares

Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
por: Xu, Qian, et al.
Publicado: (2021)

A signature-based classification of lung adenocarcinoma that stratifies tumor immunity
por: Zhang, Xun, et al.
Publicado: (2023)

PD-1 inhibitors-based second-line therapy for metastatic gastric cancer
por: Gou, Miaomiao, et al.
Publicado: (2023)

Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma
por: Zeng, Tian-mei, et al.
Publicado: (2022)

Immune Profiling in Gastric Cancer Reveals the Dynamic Landscape of Immune Signature Underlying Tumor Progression
por: Wei, Yuhan, et al.
Publicado: (2022)

A vasculogenic mimicry prognostic signature associated with immune signature in human gastric cancer
por: Wang, Jie, et al.
Publicado: (2022)

Screening and Validation of the Hypoxia-Related Signature of Evaluating Tumor Immune Microenvironment and Predicting Prognosis in Gastric Cancer
por: Pei, Jun-Peng, et al.
Publicado: (2021)

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma
por: Zhong, Yu-Min, et al.
Publicado: (2022)

Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature
por: Zhang, Chuang, et al.
Publicado: (2021)

Genetic mutation and tumor microbiota determine heterogenicity of tumor immune signature: Evidence from gastric and colorectal synchronous cancers
por: Yang, Weili, et al.
Publicado: (2022)

The cancer-associated fibroblast-related signature predicts prognosis and indicates immune microenvironment infiltration in gastric cancer
por: Mak, Tsz Kin, et al.
Publicado: (2022)

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
por: Tang, Qing, et al.
Publicado: (2022)

The Hypoxic Landscape Stratifies Gastric Cancer Into 3 Subtypes With Distinct M6a Methylation and Tumor Microenvironment Infiltration Characteristics
por: Ning, Zhi-kun, et al.
Publicado: (2022)

Construction and validation of a signature for T cell-positive regulators related to tumor microenvironment and heterogeneity of gastric cancer
por: Guo, Yangyang, et al.
Publicado: (2023)

What Is Long-Term Survival and Which First-Line Immunotherapy Brings Long-Term Survival for Advanced Wild-Type Non-Small Cell Lung Cancer: A Network Meta-Analysis Based on Integrated Analysis
por: Zhang, Xue, et al.
Publicado: (2022)

Stapled peptide PROTAC induced significantly greater anti-PD-L1 effects than inhibitor in human cervical cancer cells
por: Shi, Yu-Ying, et al.
Publicado: (2023)

Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
por: Ju, Feng, et al.
Publicado: (2023)

Serum cytokines and neutrophil-to-lymphocyte ratio as predictive biomarkers of benefit from PD-1 inhibitors in gastric cancer
por: Hou, Yidan, et al.
Publicado: (2023)

Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis
por: Tian, Yuan, et al.
Publicado: (2020)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
por: Wang, Qingyi, et al.
Publicado: (2021)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

A novel immunogenic cell death–related subtype classification and risk signature for predicting prognosis and immunotherapy efficacy in gastric cancer
por: Dong, Bingqi, et al.
Publicado: (2023)

The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors
por: Chen, Li, et al.
Publicado: (2022)

The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer
por: Zhao, Zihan, et al.
Publicado: (2023)

Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors
por: Giordan, Quentin, et al.
Publicado: (2021)

PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer
por: Zhang, Yingzi, et al.
Publicado: (2022)

Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor
por: Bai, Xin, et al.
Publicado: (2021)

Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma
por: Koh, Young Wha, et al.
Publicado: (2023)

Stemness Refines the Classification of Colorectal Cancer With Stratified Prognosis, Multi-Omics Landscape, Potential Mechanisms, and Treatment Options
por: Liu, Zaoqu, et al.
Publicado: (2022)

AURKA inhibitor-induced PD-L1 upregulation impairs antitumor immune responses
por: Meng, Bi, et al.
Publicado: (2023)

Immune landscape and prognostic gene signatures in gastric cancer: implications for cachexia and clinical outcomes
por: Sui, Xiangyu, et al.
Publicado: (2023)

The m(6)A-related gene signature stratifies poor prognosis patients and characterizes immunosuppressive microenvironment in hepatocellular carcinoma
por: Ma, Ensi, et al.
Publicado: (2023)

Identification of prognostic gene expression signatures based on the tumor microenvironment characterization of gastric cancer
por: Sang, Qingqing, et al.
Publicado: (2022)

Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
por: Jiang, Siqing, et al.
Publicado: (2022)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2018)

Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma
por: Liang, Xiaowei, et al.
Publicado: (2023)

An immune genes signature for predicting mortality in sepsis patients
por: Lin, Shirong, et al.
Publicado: (2023)

Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation
por: Wang, Qi, et al.
Publicado: (2023)

PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis
por: Yu, Yinan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d2ohqceel3o89vi6oa5dq6mq9f